Wen et al. suggested that an EGCG derivative reduced drug resistance in doxorubicin-resistant human hepatocellular carcinoma cells (BEL-7404/DOX) via downregulation of HIF-1α and p-gp [228]. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.